Navigation Links
WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai
Date:2/10/2009

SHANGHAI, China, Feb. 10 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the U.S., announced it had recently held a successful 2009 supplier conference in Shanghai.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The half-day event, with a theme of "Stick together to create a brilliant 2009," assembled 110 representatives of suppliers who provide the company with top-quality instruments and other equipment, raw materials, reagents, consumables, and related products and services. The conference provided a venue to exchange new ideas and strategies to improve the efficiency of the supply chain and to positively impact future financial and operational performance.

WuXi AppTec also took the occasion to provide special recognition to suppliers who helped the company achieve greater efficiency and cost savings. WuXi evaluates its suppliers on the basis of quality of management, quality of products, on-time delivery, customer service, and cost. To acknowledge their highly proactive and responsive service, the company presented the Preferred Supplier Award to Agilent Technologies Inc. and Service Awards to Fulltime Holdings Ltd. and Sigma-Aldrich (Shanghai) Trading Co., Ltd. Dr. Richard M. Soll, Vice President of Medicinal Chemistry, commented, "Outsourcing is now widely recognized as a highly effective and cost-efficient approach to pharmaceutical R&D. WuXi's mission is to improve the success of research and shorten the time of development of the world's leading biopharmaceutical and medical device companies. We are succeeding by offering a broad range of capabilities: an international leadership team with extensive experience in the industries we serve; a large staff of highly educated and trained scientists; broad technical expertise; world-class facilities in both China and the U.S.; and an intense focus on meeting the needs of a diversified customer base."

"2008 was a year of significant achievement for WuXi AppTec,'' said Mr. Xiaozhong Liu, Executive Vice President. ''Our governing principle is to develop new capabilities and add new capacity to provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. In that regard, we completed the acquisition of AppTec Laboratory Services, Inc., which gave our company new testing capabilities to serve biotech and medical device customers. We have now completed the integration of AppTec and look forward to building on its solid base of business.

''We also made substantial progress in 2008 in constructing two new facilities-the GLP Drug Evaluation Center in Suzhou, one of the largest in Asia, and an expansion of the manufacturing facility in the Jinshan area of Shanghai. Both facilities are now fully constructed and undergoing validation. Both provide opportunities for significant revenue growth in 2010 and beyond.

''For these initiatives and our ongoing business to be successful, we need continued support from a dedicated group of high-quality suppliers," Mr. Liu concluded. ''WuXi has been fortunate to continue to experience rapid growth in our global business despite global financial crisis. This conference is an expression of the continued commitment of WuXi and its suppliers to establish a perfect cost-efficient partnership to serve healthcare manufacturers better."

About WuXi AppTec

WuXi AppTec is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is an operating subsidiary of WuXi PharmaTech traded under NYSE symbol WX, formally WuXi PharmaTech (Cayman) Inc. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Sherry Shao
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
2. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
3. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
4. Chemical come-on successfully lures lovesick lampreys to traps
5. University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels
6. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
7. The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program
8. Pilot Program Successfully Addresses Mental Health Issues in Pennsylvanias Children
9. Perot Systems Successfully Implements Hospital Information System in Abu Dhabi
10. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
11. PreMD Successfully Completes Project for Health & Beauty Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... Los Angeles, CA (PRWEB) , ... July 24, 2017 , ... ... that will spotlight doctors and the cosmetic surgeries they perform on a daily basis. ... in performing the cosmetic surgery procedures they specialize in at their practices. , ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor ... neurological condition called essential tremor (ET). The seminar will take place on Saturday, Aug. ... Blvd., Independence, OH. The program will run from 9 a.m. to 12 p.m., with ...
(Date:7/24/2017)... ... ... people are taking more steps to protect themselves from sunburn, half of all adults and ... the past year. It’s common and people have been dealing with them since the dawn ... conscientious of the risks that accompany sunburns. , The team at AloeVera.com , a ...
(Date:7/24/2017)... ... 24, 2017 , ... A new report released today by ... sleep health care at scale, indicates record-breaking adherence results for the company’s obstructive ... airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/1/2017)... , June 30, 2017 Zimmer Biomet Holdings, Inc. ... and earnings conference call will be broadcast live over the ... Time.  A news release detailing the quarterly results will be ... the conference call. The live audio webcast can ... http://investor.zimmerbiomet.com . It will be archived for replay following the ...
Breaking Medicine Technology: